The strong counter-play between ETA and NO in CKD pathophysiology was recently supported by a rat ischemia-reperfusion injury study, where ETA down-regulation with small interfering RNA (siRNA) treatment resulted in reduced creatinine levels and inflammatory factors and alleviated renal histological damage, whereas NO expression was increased and ET-1 expression reduced. The gene discussed is EDN1; the disease is chronic kidney disease.